Cerulean Pharma Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage oncology-focused company developing nanoparticle-drug conjugates (NDCs), is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.